Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, Mineno J, Shiku H, Nishida S, Sugiyama H, Tajiri H, Homma S. Takahara A, et al. Among authors: koido s. Cancer Immunol Immunother. 2011 Sep;60(9):1289-97. doi: 10.1007/s00262-011-1033-3. Epub 2011 May 24. Cancer Immunol Immunother. 2011. PMID: 21607557 Free PMC article.
Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer.
Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S, Koido S, Nagai K, Shimodaira S, Okamoto M, Yonemitsu Y, Suzuki N, Nagaya M; DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). Kobayashi M, et al. Among authors: koido s. J Gastrointest Surg. 2013 Sep;17(9):1609-17. doi: 10.1007/s11605-013-2286-2. Epub 2013 Jul 20. J Gastrointest Surg. 2013. PMID: 23877328
Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.
Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, Tsuboi A, Oka Y, Yanagisawa S, Toyama Y, Ikegami M, Kitagawa T, Eguchi H, Wada H, Nagano H, Nakata J, Nakae Y, Hosen N, Oji Y, Tanaka T, Kawase I, Kumanogoh A, Sakamoto J, Doki Y, Mori M, Ohkusa T, Tajiri H, Sugiyama H. Nishida S, et al. Among authors: koido s. J Immunother. 2014 Feb-Mar;37(2):105-14. doi: 10.1097/CJI.0000000000000020. J Immunother. 2014. PMID: 24509173 Free PMC article. Clinical Trial.
Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, Uchiyama K, Kajihara M, Arakawa H, Misawa T, Toyama Y, Yanagisawa S, Ikegami M, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ishidao T, Yusa S, Shimodaira S, Gong J, Sugiyama H, Ohkusa T, Tajiri H. Koido S, et al. Clin Cancer Res. 2014 Aug 15;20(16):4228-39. doi: 10.1158/1078-0432.CCR-14-0314. Epub 2014 Jul 23. Clin Cancer Res. 2014. PMID: 25056373 Clinical Trial.
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Koido S, Kan S, Yoshida K, Yoshizaki S, Takakura K, Namiki Y, Tsukinaga S, Odahara S, Kajihara M, Okamoto M, Ito M, Yusa S, Gong J, Sugiyama H, Ohkusa T, Homma S, Tajiri H. Koido S, et al. Anticancer Res. 2014 Nov;34(11):6353-61. Anticancer Res. 2014. PMID: 25368235
Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
Takakura K, Koido S, Kan S, Yoshida K, Mori M, Hirano Y, Ito Z, Kobayashi H, Takami S, Matsumoto Y, Kajihara M, Misawa T, Okamoto M, Sugiyama H, Homma S, Ohkusa T, Tajiri H. Takakura K, et al. Among authors: koido s. Anticancer Res. 2015 Jan;35(1):555-62. Anticancer Res. 2015. PMID: 25550602
159 results